These four genes (PIM1, MYD88, TP53, TNFAIP3) has been identified to be the mutational drivers in DLBCL, which might partly explain the poor prognosis of patients carrying PCLO mutations (32–35). This evidence concerns the gene PCLO and diffuse large B-cell lymphoma.